title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Efficacy | SARS-CoV-2-specific T-cell memory | ASYMPTOMATIC COVID-19, EVENTS, SARS-COV-2 INFECTION | Evaluation of the ELISPOT assay test shows that 38.8% of subjects were reactive to SARS-CoV-2 S protein (significant increase of spot count) at day 14. This number increases where 62.2% of subjects were reactive to SARS-CoV-2 S protein at day 14 or day 28 (SARS-CoV-2-specific T-cell memory response.
In a 1-year observa... | PMC10315914 |
Discussion | PMC10315914 | |||
Safety | fatty liver, hypertension | FATTY LIVER, CNS INFECTIONS, RETINAL DETACHMENT, HYPERTENSION, TYPE 2 DIABETES MELLITUS, CORONARY ARTERY DISEASE | AEs that occur up to 28 days post-vaccination, based on reported data, are all mild. Non-COVID AE for up to 28 days was reported by 64.5% of phase I subjects and 53.6% of phase II subjects, and there were no significant differences between treatment groups (The short-term AE incidence rate of DC vaccines is lower compa... | PMC10315914 |
Efficacy and antigen dosage | infection, SARS-CoV-2-specific memory T | ASYMPTOMATIC COVID-19, INFECTION, COVID-19 INFECTION | ELISPOT results show that this vaccine can induce SARS-CoV-2-specific memory T cells (Although phase II aims to determine the optimal dose of antigens, in this study, we also evaluated the efficacy of this vaccine in preventing the onset of moderately and severely symptomatic COVID-19 that requires hospital treatment. ... | PMC10315914 |
Feasibility | autoimmune and cancer | This research shows that personalized DC–based vaccines can be manufactured in pandemic situations. This clinical trial was conducted in two hospital centers with a production time of 1 week. Trained staff can produce vaccines in health facilities/hospitals with specific standard preparations. This vaccine is unsuitabl... | PMC10315914 | |
Conclusion | SARS-CoV-2 infection | SARS-COV-2 INFECTION | Based on phase I and II clinical trials of DC–based COVID-19 prevention vaccines, the absence of SAE associated with vaccine administration for up to 1 year for SARS-CoV-2 infection shows good tolerability and safety. Of the three vaccine dose candidates tested, the smallest dose of 0.1 mcg provides good immunogenicity... | PMC10315914 |
Data availability statement | The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation. | PMC10315914 | ||
Ethics statement | The studies involving human participants were reviewed and approved by Gatot Soebroto Army Hospital. The patients/participants provided their written informed consent to participate in this study. | PMC10315914 | ||
Author contributions | RS, JJ | TP, YN, EL, RT, M, RS, and NS contributed to the design, implementation, and analysis of the phase I trial. JJ, TP, MY, ES, RI, and BR contributed to the design, implementation, and analysis of the phase II trial. JJ, ES, RI, ES, and YN wrote the manuscript. All authors contributed to the article and approved the submi... | PMC10315914 | |
Conflict of interest | The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. | PMC10315914 | ||
Publisher’s note | All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or ... | PMC10315914 | ||
References | PMC10315914 | |||
Background | NSCLC, tumor, death | TUMOR, METASTATIC NON-SMALL CELL LUNG CANCER, NSCLC | In CheckMate 227 Part 1 (NCT02477826), first-line nivolumab plus ipilimumab demonstrated long-term durable overall survival (OS) benefit versus chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC), regardless of tumor programmed death ligand 1 (PD-L1) expression. We report results in Japanese pat... | PMC10542710 |
Methods | NSCLC | NSCLC | Adults with stage IV/recurrent NSCLC without | PMC10542710 |
Results | At 62.1 months’ minimum follow-up, 143 Japanese patients with PD-L1 ≥ 1% or < 1% were randomized to nivolumab plus ipilimumab ( | PMC10542710 | ||
Conclusions | NSCLC, tumor | TUMOR, NSCLC | At 5-year follow-up, nivolumab plus ipilimumab continued to show long-term durable clinical benefit versus chemotherapy, regardless of tumor PD-L1 expression. Consistent with findings for the global population, these data support the use of nivolumab plus ipilimumab as first-line treatment in Japanese patients with met... | PMC10542710 |
Supplementary Information | The online version contains supplementary material available at 10.1007/s10147-023-02390-2. | PMC10542710 | ||
Keywords | PMC10542710 | |||
Introduction | NSCLC, death, tumor | TUMOR, METASTATIC NON-SMALL CELL LUNG CANCER, NSCLC | Programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitor-based immunotherapy in the first-line setting has significantly improved survival outcomes versus chemotherapy alone for patients with metastatic non-small cell lung cancer (NSCLC) [Immune checkpoint inhibitors, nivolumab, a fully human PD-1 anti... | PMC10542710 |
Patients and methods | PMC10542710 | |||
Patients and treatment | toxicity, tumor | DISEASE PROGRESSION, TUMOR | Eligibility criteria for CheckMate 227 (NCT02477826) were described previously [Patients with tumor PD-L1 expression ≥ 1% were randomized 1:1:1 to receive nivolumab (3 mg/kg every 2 weeks [Q2W]) plus ipilimumab (1 mg/kg every 6 weeks), nivolumab monotherapy (240 mg Q2W), or platinum-doublet chemotherapy (every 3 weeks ... | PMC10542710 |
Endpoints and assessments | tumor, immune-mediated adverse, death, Cancer | ADVERSE EVENT, TUMOR, ADVERSE EVENTS, SECONDARY, CANCER | The independent co-primary endpoint of OS in patients with tumor PD-L1 expression ≥ 1% and secondary endpoints were previously reported [Safety and tolerability, including treatment-related adverse events (TRAEs) and immune-mediated adverse events (IMAEs) were assessed in all treated Japanese patients. AEs were graded ... | PMC10542710 |
Statistical analyses | tumor | TUMOR | Efficacy and safety analyses of nivolumab plus ipilimumab versus chemotherapy in the randomized and treated populations, respectively, of Japanese patients were exploratory and summarized using descriptive statistics. Time-to-event analyses for OS, PFS, DOR, and TFI were performed using the Kaplan–Meier method. Hazard ... | PMC10542710 |
Results | PMC10542710 | |||
Efficacy outcomes | PMC10542710 | |||
Patients alive at 5 years | In the combined PD-L1 ≥ 1% and < 1% population, 47 Japanese patients were alive at 5 years (nivolumab plus ipilimumab: PFS in Japanese patients alive at 5 years (PD-L1 ≥ 1% and < 1%). At the 5-year cut-off, 59% (95% CI, 39%–75%) of patients in the nivolumab plus ipilimumab arm versus 15% (95% CI, 4%–34%) in the chemoth... | PMC10542710 | ||
Discussion | NSCLC, tumor, cancers, melanoma, TRAEs | TUMOR, CANCERS, MELANOMA, EVENT, DISEASE, NSCLC | The results of this subanalysis in Japanese patients from the CheckMate 227 Part 1 study represent the longest survival follow-up reported to date for phase 3 studies evaluating first-line combination immunotherapy for metastatic NSCLC with tumor PD-L1 ≥ 1% or < 1%. With a 5-year minimum follow-up, clinically meaningfu... | PMC10542710 |
Acknowledgements | The authors thank the patients and their families, as well as the clinical study teams, for making this study possible; Faith E. Nathan, MD, who served as the clinical trial physician; and Suresh Alaparthy, who served as the global trial manager. This study was funded by Bristol Myers Squibb. The PD-L1 IHC 28-8 pharmDx... | PMC10542710 | ||
Author contributions | HT | Patient treatment and data collection were performed by MN, YO, SI, TY, HH, TF, YS, HT, KH, SS, HD, IO, KK, TN and HM. Data analysis was performed by LL, RGG and JB. All authors contributed to the interpretation of results and preparation of the manuscript. All authors have read and approved the final manuscript. | PMC10542710 | |
Data availability | Data are available upon reasonable request. BMS policy on data sharing may be found at | PMC10542710 | ||
Declarations | PMC10542710 | |||
Conflicts of interest | EPS | ONCOLOGY | H.D. received honoraria from AstraZeneca and Chugai Pharmaceutical. H.H. received honoraria from Amgen K.K., AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Kyorin Pharmaceutical... | PMC10542710 |
Ethical approval | The institutional review board or independent ethics committee at each center approved this trial and it was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. All patients provided written informed consent. The trial protocol ha... | PMC10542710 | ||
References | PMC10542710 | |||
Keywords | WARTS, PLANE WARTS | Immunotherapy represents a promising therapeutic option for treatment of warts. Different concentrations of Candida antigen (1/100 and 1/1000) and zinc sulfate 2% were not previously compared regarding their efficacy in treatment of cutaneous warts. The present study compared the safety and efficacy of intralesional ca... | PMC10205831 | |
Introduction | wart | HYPERSENSITIVITY RESPONSE, WART, RECURRENCE, HPV INFECTION, WARTS, MUMPS, PLANE WARTS | Two therapeutic options are used for treatment of warts: the first is the destructive method, like chemical cautery, cryotherapy, electrocauterization, surgical excision, and laser ablation, which are painful and with common recurrence [Intralesional (IL) immunotherapy with different skin test antigens like Candida, mu... | PMC10205831 |
Study design | COMPLICATIONS | This randomized controlled prospective clinical study (simple randomization) was approved by the Institutional Ethics and Research Committee of Faculty of Medicine, Assiut University, Assiut, Egypt, with clinical trial registration number (Clinical Trials.gov Identifier: NCT03158168). A written informed consent was obt... | PMC10205831 | |
Patients and methods | PLANE WARTS | A total of 105 randomly selected patients, presented with multiple palmar, plantar, and/or plane warts, were enrolled in the study from March 2018 to March 2020 and completed the study. They were recruited from the Outpatient Clinic of Dermatology Department, Assiut University Hospital. | PMC10205831 | |
Inclusion criteria | PLANTAR WARTS, WARTS, VIRAL WARTS | Patients with cutaneous (extragenital) viral warts (single or multiple, new, or recurrent, common, plane and plantar warts) of different sizes and durations and with or without distant warts (warts in different anatomical sites) were included. There is no concurrent systemic or topical treatment for warts. Age ranged f... | PMC10205831 | |
Statistical analysis | Data entry and data analysis were done using SPSS version 22 (Statistical Package for Social Science). Data were presented as number, percentage, mean, median, and standard deviation. Chi-square test was used to compare qualitative variables. Mann–Whitney test was used to compare quantitative variables between two grou... | PMC10205831 | ||
Author contributions | The authors contributed equally in the study design and patient's treatment, writing and reviewing the main manuscript text, preparing figures,data collection and analysis. | PMC10205831 | ||
Funding | Open access funding are provided by The Science, Technology& Innovation Funding Authority (STDF) in cooperation with the Egyptian Knowledge Bank (EKB). | PMC10205831 | ||
Data availability statement | The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request. | PMC10205831 | ||
Declarations | PMC10205831 | |||
Competing interests | The authors have no conflict of interest to declare. | PMC10205831 | ||
Ethical approval | All procedures performed in this randomized controlled prospective clinical study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Instituti... | PMC10205831 | ||
Informed consent | COMPLICATIONS | A written informed consent was obtained from each patient or their guardians in case of children, after informing him/her about the technical and scientific basis of the research, the steps of the procedure, and the expected effects or possible complications. | PMC10205831 | |
References | PMC10205831 | |||
1. Introduction | Coffeeberry extract, fatigue | Background: Coffeeberry extract, rich in chlorogenic acids, shows promise in improving mood and cognition, particularly when co-supplemented with phenolic compounds. However, limited work has considered the effects of coffeeberry in isolation, especially at low doses. Objective: The current study investigated the effec... | PMC10254646 | |
2. Materials and Methods | PMC10254646 | |||
2.1. Study Design and Participants | BRAIN | The study followed a randomised, double-blind, placebo-controlled crossover design with four study arms. Research took place from July 2021 to January 2022 at the Brain, Performance and Nutrition Research Centre (BPNRC) at Northumbria University. The Northumbria University Health and Life Sciences Ethics Committee revi... | PMC10254646 | |
2.2. Treatments | When attending each of the four testing visits, participants were given one of four beverages (labelled A, B, C, D) via random allocation according to a counterbalancing order (Latin square) that was generated by computer. Specifically, participants were block randomized to one of eight possible treatment orders (ABCD,... | PMC10254646 | ||
2.3. Cognitive and Mood Assessment | fatigue, alertness | The cognitive function tests were administered to participants using the Computerised Mental Performance Assessment System (COMPASS, Northumbria University, Newcastle upon Tyne, UK). COMPASS allows for bespoke task batteries to be designed as needed, with randomised parallel versions of the tasks being administered at ... | PMC10254646 | |
2.4. Procedure | HOLIDAY, COVID-19 INFECTION | Participants were required to attend six appointments: a remote screening appointment, a training appointment, and four test visits. The remote screening visit was conducted over the telephone, and it comprised a briefing on the requirements of the study, the signing of a virtual consent form, review of the inclusion a... | PMC10254646 | |
2.5. Statistics | cognitive and mood, fatigue | All cognitive and mood outcome measures were modelled using the MIXED procedure in SPSS (version 26.0, IBM Corp., Armonk, NY, USA). For the episodic memory outcomes, the post dose data were modelled including treatment as a fixed effect. For the CDB task and VAS outcomes, changes from baseline values were modelled with... | PMC10254646 | |
3. Results | Of the seventy-five participants who were randomized to receive treatment, three participants discontinued following testing visit 1, and one discontinued following testing visit 2. Of these four participants who discontinued, three were replaced and one could not be replaced due to time constraints of the study timeli... | PMC10254646 | ||
3.1. Response to Coffeeberry | PMC10254646 | |||
3.1.1. Mood and Psychological State | (CDB).A, fatigue | For the primary endpoints, a priori pairwise comparisons of change from baseline data collected at 120 min post dose revealed no significant effect of treatment on either the mental fatigue or alertness scales (CDB).A priori pairwise comparisons of change from baseline data collected at 60 min post dose revealed the me... | PMC10254646 | |
3.1.2. Cognitive Performance | A priori pairwise comparisons of change from baseline data, collected at 60 and 120 min post dose, revealed that 100 mg coffeeberry significantly decreased RVIP accuracy at 60 min post dose compared to placebo (No other significant comparisons were observed. See | PMC10254646 | ||
3.2. Response to Caffeine (Positive Control) | The analysis revealed that of the 25 outcome measures that were collected at each of the two post dose assessments, a significant main effect of treatment was observed for 24 of these. Pairwise comparisons revealed a consistent alerting and performance enhancing effect of the positive control beverage containing 75 mg ... | PMC10254646 | ||
4. Discussion | fatigue | The results of the current study suggest that the consumption of 300 mg coffeeberry extract has no effect on mood, performance of cognitively demanding tasks, or episodic memory up to 120 min post dose. Limited results were observed following 100 mg coffeeberry, which followed a pattern of negative effects. Specificall... | PMC10254646 | |
Supplementary Materials | The following supporting information can be downloaded at: Click here for additional data file. | PMC10254646 | ||
Author Contributions | P.A.J., D.O.K. and J.J. contributed to the design of the protocol; C.K. and B.S. collected the data; J.F. supervised data collection; P.A.J. analysed the data; P.A.J., E.F.S. and R.E. prepared the initial draft of the manuscript. All authors have read and agreed to the published version of the manuscript. | PMC10254646 | ||
Institutional Review Board Statement | The study was conducted in accordance with the Declaration of Helsinki, and the Northumbria University Health and Life Sciences Ethics Committee reviewed and approved all study procedures used (reference code 33646 on 24 June 2021). | PMC10254646 | ||
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC10254646 | ||
Data Availability Statement | The data presented in this study are available upon request from the corresponding author. The data are not publicly available due to data sharing and privacy regulations in Europe and UK. | PMC10254646 | ||
Conflicts of Interest | J.J. is an employee of PepsiCo, the sponsor of the study. J.J. contributed to the design of the protocol and provided comments on the manuscript but had no role in collection, analysis, or interpretation of the results. The views expressed in this article are those of the authors and do not necessarily reflect the posi... | PMC10254646 | ||
References | fatigue | Participant disposition flowchart.Timeline of the testing visit assessment schedule. CDB, Cognitive Demand Battery; EFS-State, mental and physical energy and fatigue scales.Estimated marginal means of change from baseline values (±SE) derived from the linear mixed model for the Cognitive Demand Battery (CDB) ‘Mental Fa... | PMC10254646 | |
Methods | Tele-midwifery | Seventy primiparous women attending the prenatal clinic of Baharlou Hospital in Tehran, Iran, were randomly assigned to two parallel intervention and control groups with 35 participants each. Women in the intervention group received Tele-midwifery for eight weeks, whereas women in the control group only received routin... | PMC10619799 | |
Results | There was a significant decrease in FOC among women in the intervention group compared to control groups after eight weeks of intervention (- 20.9 [95% Confidence Interval,—24.01 to—17.83], p < 0.001), and after birth (- 30.8, [95% CI—33.8 to—27.97], p < 0.001). After eight weeks, the mean self-efficacy score in the in... | PMC10619799 | ||
Conclusions | Tele-midwifery | Tele-midwifery intervention reduced FOC, increased women’s self-efficacy in childbirth, and decreased the number of CS in a group of first-time mothers. Healthcare providers can use the mHealth approach to support pregnant women with FOC. | PMC10619799 | |
Trial registration | Registration number: IRCT20200122046227N1, Registered on 27 January 2020. | PMC10619799 | ||
Data Availability | The authors confirm all the data collected in this study has been thoroughly presented within the paper. However, this study was conducted in a single center over a short period of time, so making the data set public may lead to participant identification. Data set will be available upon request from the ethics committ... | PMC10619799 | ||
Introduction | traumatic childbirth | COMPLICATIONS | Fear of childbirth (FOC) is a well-known problem affecting women, especially primiparous during pregnancy and postpartum period [Even though various interventions such as yoga, art therapy, and counseling, have been shown to be effective in reducing FOC, there is no consensus regarding the best treatment for alleviatin... | PMC10619799 |
Materials and methods | PMC10619799 | |||
Study design and eligibility criteria | Tele-midwifery, fetus abnormalities | PLACENTAL ABRUPTION, CHRONIC DISEASES, PREECLAMPSIA | We conducted a Randomized Clinical Trial (RCT) to evaluate the effectiveness of using an mHealth application called Tele-midwifery to reduce FOC, increase childbirth self-efficacy, and reduce the number of CS among primiparous women. The research setting was the perinatal clinic of Baharlou Hospital in Tehran, Iran, an... | PMC10619799 |
Outcomes | SECONDARY | The primary outcome of this study was a change in FOC score. The secondary outcomes were a change in childbirth self-efficacy score, and childbirth mode. | PMC10619799 | |
Measures | In this study, the fear related to childbirth in the prenatal and postnatal period was measured using W-DEQ versions A and B. W-DEQ version A evaluates women’s prenatal expectances before childbirth, and W-DEQ version B evaluates experiences with recent childbirth. Each version contains 33 items with a 6-point Likert s... | PMC10619799 | ||
Sample size | The sample size was calculated based on our primary outcome which was FOC. We referred to the results of Gözde Birsbir et al.’s (2016) study on the effect of antenatal education on FOC to estimate our sample size [ | PMC10619799 | ||
Procedures | Tele-midwifery | RECRUITMENT | A convenience sampling approach was used, and a consecutive sample of pregnant women attending to the selected prenatal clinic for receiving their routine prenatal care were evaluated using their medical records for inclusion and exclusion criteria, by a colleague not involved in the study. Afterward, the objectives of... | PMC10619799 |
CONSORT flow diagram of the study. | Tele-midwifery | A randomized allocation into two groups of intervention and control with a 1: 1 ratio took place during the routine prenatal visit in the hospital. A colleague who was not involved in the study put each computerized generated random sequences separately in sealed and opaque envelopes. To mask the person performing the ... | PMC10619799 | |
Tele-midwifery application | Tele-midwifery | First, to prepare the Tele-midwifery application’s content, reliable and up-to-date scientific sources such as textbooks, scientific articles, related guidelines, studied carefully by the research team, and necessary content in various fields were reviewed [ | PMC10619799 | |
Dimensions of intervention | PMC10619799 | |||
Education | labor pain, Tele-midwifery | COMPLICATIONS | The educational content of the Tele-midwifery application was designed to include all possible causes of FOC in Iranian women, such as fear of labor pain, lack of information related to the mother and baby’s health, what women should expect during labor and birth, the characteristics of each stage of labor, misconcepti... | PMC10619799 |
Five components of educational content of Tele-midwifery application. | PMC10619799 | |||
Continuous support and engagement of women | To provide continuity of care and support between two prenatal visits, participants in the intervention group, could contact the researchers if they had concerns and questions about their pregnancy and birth care. The team of researchers including midwives and obstetricians were available throughout the day (between 7 ... | PMC10619799 | ||
Statistical analyzes | REGRESSION | The data analyzed by IBM SPSS statistics version 25 and p-value > 0.05 was considered as a statistically significant level. To compare statistical differences of demographic data in intervention and control groups, an independent t-test, Chi-square test, and Fisher’s exact test were used. The repeated-measures analysis... | PMC10619799 | |
Ethical considerations | The ethics committee of Tehran University of Medical Sciences approved the research procedure (IR.TUMS.FNM.REC.1398.135). At the beginning of the study, the researchers provided the necessary explanations about the intervention and the study’s objectives to the participant. After receiving sufficient information from v... | PMC10619799 | ||
Results | A total of 70 nulliparous women with FOC enrolled in the study in two intervention (n = 35) and control (n = 35) groups. There was no loss to follow-up, and no exclusion from the study based on our criteria, and although we prepared to refer participants in case of an emergency, no such contacts were made during the st... | PMC10619799 | ||
Characteristics of the participants. | (n = 70).*Fisher Exact Test**Chi square test***Independent t-test | PMC10619799 | ||
FOC | REGRESSION | A repeated-measures ANOVA with a Greenhouse-Geisser correction for within-subject effects of FOC scores showed that time and the group interaction effect is significant for this variable (time*group: F = 131, p < 0.001). To compare groups at different time-points (baseline, after 8 weeks, and after childbirth), linear ... | PMC10619799 | |
Comparison of FOC scores in intervention and control groups at baseline, after 8 weeks and after childbirth. | PMC10619799 | |||
Effect of mHealth application on FOC score in intervention group compared to control group at different time points (n = 70). | SE | SE = Standard Error, CI = Confidence Interval, LL = lower Limit, UL = Upper Limit | PMC10619799 | |
Childbirth self-efficacy | REGRESSION | There was no statistically significant difference in mean scores of childbirth self-efficacy between the intervention and control groups at the baseline (p = 0.07). According to the result of linear regression it is estimated that on average those in the intervention group have an 85.60scores more than those in the con... | PMC10619799 | |
Effect of mHealth application on self-efficacy score in intervention group compared to control group at baseline and 8 weeks after intervention (n = 70). | SE | SE = Standard Error, CI = Confidence Interval, LL = lower Limit, UL = Upper Limit | PMC10619799 | |
Birth mode | REGRESSION | Two intervention and control groups had a statistically significant difference in their birth mode (p = 0.03). The intervention group had a lower rate of CS than the control group (31.4% in the intervention group versus 60% in the control group). The result of the logistic regression showed that the odds of CS are appr... | PMC10619799 | |
Discussion | Tele-midwifery | This study aimed to determine the effect of an interactive mHealth application named Tele-midwifery based on education and continuous support provided by midwives on FOC, childbirth self-efficacy, and birth mode in primiparous women. Based on the results of this study, Tele-midwifery application reduced FOC, increased ... | PMC10619799 | |
Strengths and limitations of research | Tele-midwifery | This study was conducted during the COVID-19 pandemic; thus, it can be complicated to generalize the study’s results to normal conditions. Lack of access to childbirth preparation classes and the high risk of getting infected by in-person visits caused pregnant women to raise more concerns about their health. Therefore... | PMC10619799 | |
Implications for future research | PRETERM BIRTH | In this study, participants received continuous support for addressing their questions throughout the week. However, replicating such personalized attention on a larger scale could be challenging. Real-world implementation might lack sufficient qualified healthcare professionals in the field of obstetrics, potentially ... | PMC10619799 | |
Conclusion | Tele-midwifery | In this randomized clinical trial, women who received the Tele-midwifery intervention reported less FOC and more childbirth self-efficacy after receiving the Tele-midwifery application. Furthermore, the rate of CS decreased in the intervention group. Based on the results, the mHealth application can be considered a sup... | PMC10619799 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.